Biomason Raises $65 Million Series C Round to Scale Biocement® Technology.
U.S. based start-up Biomason
recently announced a $65M funding round led by 2150 with participation from Celesta Capital, Hartree Partners, and others, including current shareholders Novo Holdings and Martin Marietta Materials (MLM). The Series C funding will
accelerate development of Biomason’s proprietary biocement® technology platform to reach its goal of eliminating 25% of global carbon emissions from the concrete industry by 2030.
The only company in the world using biology to commercially produce cement, Biomason employs natural microorganisms to grow biocement in ambient temperatures without emitting carbon dioxide. Its patented biocement technology mimics nature’s use of carbon as a building block, creating cement in a biological, circular system, rather than relying on the 200-year-old climate-intensive Portland cement (OPC) production process. Biomason creates cement in a fundamentally different way, addressing the root cause of emissions.#News#Construction#NetZero#Concrete#Sustainability#GreenTechnology